Irandokht SHENAVAR MASOOLEH, Asghar HAJIABBASI, Habib ZAYENI, Atefeh GHANBARI, Violet ZAKER ESTEGHAMATI, Banafsheh GHAVIDEL PARSA, Amir HASSANKHANI

Anticyclic citrullinated peptide antibody in rheumatoid arthritis:a cross-sectional study in Iran

Background/aim: Studies have shown that anticyclic citrullinated peptide antibody (anti-CCP) titers can be useful in the diagnosis of rheumatoid arthritis (RA). We evaluate the association between anti-CCP antibody titers and the demographic, clinical, and laboratory characteristics of RA patients. Moreover, we explore whether there is any relation between joint destruction and demographic and clinical characteristics of RA patients. Materials and methods: One hundred and four RA patients with positive anti-CCP titers were compared to 104 RA patients with negative anti-CCP titers. The activity of RA was evaluated using the Disease Activity Score 28 (DAS28). Joint destruction was assessed in the subjects by X-rays of the wrists. Blood samples were collected for assessment of anti-CCP, rheumatoid factor (RF), and erythrocyte sedimentation rate. Results: Forty-eight (23.0%) males and 160 (76.9%) females were included in this study. RF, DAS28, and joint destruction were significantly different between patients with and without anti-CCP (P < 0.0001). DAS28, duration of disease, hospitalizations, and occupation differed significantly between patients with and without joint destruction (P < 0.0001). Conclusion: This study indicates that anti-CCP is correlated with a high disease activity index and more joint destruction in RA patients and it may be used as a prognostic factor for RA.

PDF

___

1. Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS. Harrisons Principles of Internal Medicine. 16th ed. New York, NY, USA: McGraw-Hill; 2005.
2. Jefferies WM. The etiology of rheumatoid arthritis. Med Hypotheses 1998; 51: 111-114.
3. Lipson SJ. Rheumatoid arthritis of the cervical spine. Clin Orthop Relat R 1984: 143-149.
4. Bongi SM, Manetti R, Melchiorre D, Turchini S, Boccaccini P, Vanni L, Maggi E. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 2004; 37: 495-501.
5. Arıdoğan BC, Kaya S, Savaş S, Çetin ES, Akkuş S, Demirci M. The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis. Mikrobiyol Bul 2008; 42: 669- 674.
6. Araki C, Hayashi N, Moriyama M, Morinobu S, Mukai M, Koshiba M, Kawano S, Kumagi S. Usefulness of anti-cyclic citrullinated peptide antibodies (anti-CCP) for the diagnosis of rheumatoid arthritis. Rinsho Byori 2004; 52: 966-972.
7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-2581.
8. Balsa A, Carmona L, Gonzalez-Alvaro I, Belmonte MA, Tena X, Sanmarti R; EMECAR Study Group. Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004; 31: 40-46.
9. Wolfe F. A comparison of IgM rheumatoid factor by nephelometry and latex methods: clinical and laboratory significance. Arthrit Care Res 1998; 11: 89-93.
10. Subramanian A, Rangarajan K, Pandey RM, Gandhi JS, Sharma V, Bhoi SK. Evaluation of an automated erythrocyte sedimentation rate analyzer as compared to the Westergren manual method in measurement of erythrocyte sedimentation rate. Indian J Pathol Micr 2011; 54: 70-74.
11. Spadaro A, Riccieri V, Alessandri C, Scrivo R, Valesini G. Usefulness of anti-cyclic citrullinate peptide antibody determination in synovial fluid analysis of patients with rheumatoid arthritis. Reumatismo 2006; 58: 116-120.
12. da Mota LM, Dos Santos Neto LL, de Carvalho JF, Pereira IA, Burlingame R, Menard HA, Laurindo IM. The presence of anticitrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years. Rheumatol Int 2012; 32: 3807-3812.
13. Del vla del Amo N, Ibanez Bosch R, Fito Manteco C, Gutierrez Polo R, Loza Cortina E. Anti-cyclic citrullinated peptide antibodies and rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 2006; 24: 281-286.
14. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, Montgomery DS, Binks MH, Wilson AG. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 2006; 8: R128.
15. Goronzy JJ, Matteson EL, Fulbright JW, Warrington KJ, Chang-Miller A, Hunder GG, Mason TG, Nelson AM, Valente RM, Crowson CS et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004; 50: 43-54.
16. Guillemin F, Gerard N, van Leeuwen M, Smedstad LM, Kvien TK, van den Heuvel W; EURIDISS Group. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. J Rheumatol 2003; 30: 2585- 2589.